Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2017

View Archived Issues

Regenxbio initiates phase I trial of gene therapy RGX-314 for wet AMD

Phase II trial of XEN-801 for acne does not meet efficacy endpoints

BARDA elects not to exercise options for AEOL-10150 development for ARS and DEARE

Xeljanz approved in Europe

AbbVie begins first-in-human trial of ABBV-621

Dacomitinib shows efficacy against penile squamous cell carcinoma

Levosimendan does not result in lower 30-day mortality in high risk cardiac surgery patients

KPR-2579, a novel TRPM8 antagonist for the potential treatment of bladder hypersensitivity

Erytech and Fox Chase to advance preclinical development of erymethionase for homocystinuria

Initiation of phase II trial of LN-145 in patients with squamous cell carcinoma of the head and neck

Epicentre presents phase III efficacy and safety results for oral BRV-PV rotavirus vaccine

Matinas reports topline phase I data on MAT-2501

Synergy submits supplemental NDA for Trulance in IBS-C

Numab and Ono Pharmaceutical enter immuno-oncology research and option agreement

Oncology Venture to evaluate Eisai drug for potential in-licensing

Amryt initiates phase III trial of AP-101 for epidermolysis bullosa

FDA approves Zejula for the maintenance treatment of women with recurrent ovarian cancer

ImMAGE Biotherapeutics advances immunotherapy for triple-negative breast cancer

Infectex reports results from phase IIb/III trial of SQ-109 for multidrug-resistant pulmonary TB

Sumitomo Dainippon Pharma presents Nav1.7 channel blockers

F. Hoffmann-La Roche AG patents gamma-secretase inhibitors

FDA grants priority review to Ryanodex NDA to treat exertional heat stroke

Genentech and F. Hoffmann-La Roche AG divulge PI3Kalpha inhibitors

European Commission gives conditional approval to DuPont and Dow Chemical Company's merger of equals

Vaximm updates on lead compound VXM-01 at BIO-Europe Spring

Foamix reports phase III topline results for FMX-101 in moderate to severe acne

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...